Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
Experimental cell therapy targets Virus-Driven cancers in vulnerable patients
Disease control Recruiting nowThis study is testing an experimental cell therapy called tabelecleucel for cancers and tumors caused by the Epstein-Barr virus (EBV) in people with weakened immune systems. The treatment involves giving patients specially prepared immune cells designed to fight EBV-infected cell…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
Experimental cell therapy offers hope for transplant patients with rare Virus-Driven cancer
Disease control Recruiting nowThis study is testing an experimental cell therapy called tabelecleucel for transplant patients who develop a rare cancer caused by Epstein-Barr virus. The treatment uses specially prepared immune cells to target and fight the virus-related cancer in patients who haven't responde…
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First human trial launches for targeted lung cancer treatment
Disease control Recruiting nowThis study is testing a new drug called STX-721/PFL-721 for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR or HER2 exon 20 insertions). The trial aims to find the safest and most effective dose while checking if the drug can shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill targets Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing a new oral medication called STX-241 for people with advanced non-small cell lung cancer (NSCLC) that has continued to grow despite treatment with standard targeted drugs (EGFR TKIs). The main goals are to find a safe and effective dose and to see if the dru…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC